Barclays Lowers Agilon Health (NYSE:AGL) Price Target to $0.50

Agilon Health (NYSE:AGL) had its target price cut by stock analysts at Barclays from $1.00 to $0.50 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “underweight” rating on the stock. Barclays‘s price target suggests a potential downside of 14.97% from the company’s previous close.

Several other research analysts also recently commented on the company. Wells Fargo & Company cut their target price on Agilon Health from $1.50 to $1.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. BTIG Research restated a “neutral” rating on shares of Agilon Health in a research report on Friday, December 12th. Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a report on Wednesday, December 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a report on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $2.60.

Agilon Health Trading Down 1.1%

NYSE AGL opened at $0.59 on Friday. The firm’s 50 day simple moving average is $0.71 and its 200 day simple moving average is $0.85. The firm has a market capitalization of $243.94 million, a price-to-earnings ratio of -0.62 and a beta of 0.06. Agilon Health has a 1 year low of $0.34 and a 1 year high of $6.08.

Agilon Health (NYSE:AGL) last issued its earnings results on Wednesday, February 25th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.19). Agilon Health had a negative return on equity of 100.06% and a negative net margin of 6.60%.The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.46 billion. On average, equities research analysts forecast that Agilon Health will post -0.59 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Agilon Health by 3.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 214,200 shares of the company’s stock worth $927,000 after buying an additional 7,209 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its stake in Agilon Health by 28.4% in the first quarter. Dynamic Technology Lab Private Ltd now owns 47,111 shares of the company’s stock valued at $204,000 after acquiring an additional 10,424 shares during the last quarter. Apollon Wealth Management LLC grew its position in shares of Agilon Health by 17.4% during the 4th quarter. Apollon Wealth Management LLC now owns 82,348 shares of the company’s stock valued at $57,000 after acquiring an additional 12,193 shares during the period. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in shares of Agilon Health during the 2nd quarter worth approximately $31,000. Finally, Legal & General Group Plc increased its stake in shares of Agilon Health by 4.1% during the 2nd quarter. Legal & General Group Plc now owns 346,031 shares of the company’s stock worth $796,000 after purchasing an additional 13,700 shares during the last quarter.

Key Agilon Health News

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Wells Fargo upgraded AGL to “overweight” and raised its price target to $1.50 (from $1.00), implying meaningful upside from current levels — a bullish analyst signal that can support buying interest. Benzinga
• Neutral Sentiment: Q4 results were mixed: revenue beat estimates ($1.57B vs. ~$1.46B) but EPS missed materially (reported ($0.46) vs. consensus ($0.27)), leaving investors weighing top-line strength against profitability issues. Earnings Release/Transcript
• Neutral Sentiment: Management outlined a 2026 target (~$5.5B revenue and breakeven adjusted EBITDA) as part of a transformation plan — a constructive medium‑term goal but one that may be viewed skeptically given recent misses and execution risk. Seeking Alpha
• Negative Sentiment: Company guidance was lower than Street expectations (FY revenue midpoint and Q1 revenue below consensus), which increases downside risk as analysts rework models and investor confidence is tested. Seeking Alpha
• Negative Sentiment: Barclays cut its price target to $0.50 and moved to “underweight,” signaling additional analyst pessimism and potential further selling pressure. Benzinga
• Negative Sentiment: Multiple law firms have filed or are soliciting lead-plaintiff interest in securities class actions alleging fraud tied to Agilon, with several deadline reminders for March 2, 2026 — legal overhang and potential litigation costs are weighing on sentiment. GlobeNewswire

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.